$LLY
LLY · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for LLY…
AI-generated for information only — not investment advice.
Share this ticker
$LLY Stanley Druckenmiller and 4 other tracked billionaires hold it. $JNJ $NTRA $BHC https://billionairestrading.com/stocks/LLY
Company summary
Diabetes and GLP-1 obesity drugs.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest LLY news
- Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
Eli Lilly and Company’s (NYSE:LLY) Mounjaro has already become a major growth driver in diabetes treatment, and its latest FDA approval could strengthen that position by expanding what physicians can use the drug to accomplish. The FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who […]
Tue, 08 Sep 2026 00:14:26 +0000
- Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.
Mon, 07 Sep 2026 21:35:00 +0000
- Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Mon, 07 Sep 2026 14:03:00 +0000
- Eli Lilly’s $100B incretin opportunity: Is more upside coming?
Investing.com -- Eli Lilly & Co is positioned for further growth in the booming obesity-drug market, with its Zepbound and Mounjaro treatments and a pipeline of next-generation therapies offering multiple avenues for upside, J.P. Morgan said in a research note.
Sun, 06 Sep 2026 21:49:22 +0000
- Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
Is this big pharma stock still a buy for investors who aren't billionaires?
Sun, 06 Sep 2026 09:11:00 +0000
- Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years
Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.
Sat, 05 Sep 2026 21:08:00 +0000
- Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.
Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.
Sat, 05 Sep 2026 18:52:00 +0000
- Lilly Launches Foundayo in the UK as NICE Review Continues
Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]
Sat, 05 Sep 2026 00:47:26 +0000